Turkey

Turk Traktor: Q322 review – Stronger than expected results

  • Turk Traktor posted TL653mn net income in 3Q22, 24% higher than our estimate and 22% higher than consensus estimate.

  • The company posted TL920mn EBITDA, 15% above our estimate of TL800mn and 17% above consensus estimate of TL785mn

  • EBITDA margin of 16.0% was 85ps higher than our estimate of 15.2% (Consensus: 14.8%).

https://cdn.tellimer.com/providers/badge-ata-invest-bZ2qBXVWtZfl26qH3OLjfMn9TkdTsjoY6bSn27iv.png
Zeynep Erman @ ATA Invest
October 31st, 2022
This is a premium report that requires access to ATA Invest
ATA Invest ATA Invest

Coverage

Turkey

About

ATA Holding is a third-generation family-owned conglomerate, primarily active in financial services, food & retail, technology and rea estate. ATA Group consists of more than 20 companies, with a total consolidated sales figure exceeding US$2.0bn.

Services

Personal solutions
Add-on
This includes investment consultancy, asset management, pension services, and more.
Corporate solutions
Add-on
We offer comprehensive services relating to mergers and acquisitions and privatisation products
Full list of services

Recommendations

Access to recommendations is a Pro feature.

Most Read

1 ∙ Strategy Note ∙ Global
Fixed income strategy: 2024 outlook – pick your battles
2 ∙ Strategy Note ∙ Global
6 lessons from EM Equities in 2023
3 ∙ Macro ∙ Pakistan
Pakistan IMF review sparks rally amid improved external trade and inflation
4 ∙ Macro ∙ Global
US rate cycles: How long do peak rates last?
5 ∙ Macro ∙ Global
Kenya to abandon Eurobond plan, Bank of Mauritius leaves rates unchanged

Disclosures

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not constitute investment recommendation, and nor is it investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument.

This publication is not intended for distribution to, or use by, any person or entity in any jurisdiction in any country where such distribution or use would be contrary to law or regulation, or which would subject Tellimer to any registration requirement within such jurisdiction or country.

This research is produced by a third party. The Tellimer team has had no editorial input into the content of the note.